Labcorp has released results with notable highlights regarding its Q1 2025 performance. Despite earnings and revenues falling short of estimates, strong growth and innovation have been documented, leading to its buy rating justification. The company declared a quarterly dividend of $0.72, with the dividend and stock price doing well despite the revenue shortfall. Labcorp has also expanded its precision oncology portfolio, introducing FDA-authorized liquid biopsy tests; the decision to acquire select assets from BioReference Health's innovative oncology will increase the company's offerings. Strong Q4 sales have been reported with its full-year outlook slightly exceeding predictions. Labcorp upgraded to Outperform and set to report further Q4 earnings. A steady growth is foregrounded due to LabCorp testing diagnostic arm. Labcorp Holdings Inc Reports Q4 Revenue of $3.33 Billion, Exceeding Estimates; EPS Falls Short at $1.70. The company is set to announce more financial results on April 29, 2025.
Laboratory Corporation of America Holdings LH News Analytics from Mon, 03 Jul 2023 07:00:00 GMT to Fri, 02 May 2025 02:10:24 GMT - Rating 6 - Innovation 8 - Information 7 - Rumor -4
